Argenx to acquire PRV for $102M

Argenx announced an agreement to acquire a FDA Priority Review Voucher, or PRV, for $102M. A PRV entitles the holder to FDA priority review of a single biologics license application, or BLA, which reduces the target review period and may lead to an expedited approval. Argenx expects to redeem the PRV for a future marketing application for efgartigimod, its first-in-class neonatal Fc receptor blocker.